Commerce Bank Has $624,000 Stake in Catalent, Inc. (NYSE:CTLT)

Commerce Bank raised its stake in Catalent, Inc. (NYSE:CTLT) by 14.8% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 4,695 shares of the company’s stock after buying an additional 607 shares during the period. Commerce Bank’s holdings in Catalent were worth $624,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Catalent by 0.3% during the second quarter. Vanguard Group Inc. now owns 18,331,319 shares of the company’s stock worth $1,981,982,000 after purchasing an additional 47,141 shares during the period. BlackRock Inc. raised its position in shares of Catalent by 2.4% during the second quarter. BlackRock Inc. now owns 14,324,097 shares of the company’s stock worth $1,548,720,000 after purchasing an additional 335,336 shares during the period. State Street Corp raised its position in shares of Catalent by 3.8% during the second quarter. State Street Corp now owns 6,613,376 shares of the company’s stock worth $715,038,000 after purchasing an additional 240,541 shares during the period. JPMorgan Chase & Co. raised its position in shares of Catalent by 5.2% during the second quarter. JPMorgan Chase & Co. now owns 4,748,293 shares of the company’s stock worth $513,386,000 after purchasing an additional 232,981 shares during the period. Finally, Northern Trust Corp raised its position in shares of Catalent by 0.7% during the second quarter. Northern Trust Corp now owns 1,676,029 shares of the company’s stock worth $181,212,000 after purchasing an additional 11,115 shares during the period. 97.12% of the stock is currently owned by institutional investors.

In other news, insider Karen Flynn sold 2,472 shares of the firm’s stock in a transaction that occurred on Monday, January 10th. The stock was sold at an average price of $116.64, for a total value of $288,334.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gregory T. Lucier sold 5,068 shares of the firm’s stock in a transaction that occurred on Tuesday, November 23rd. The shares were sold at an average price of $127.35, for a total value of $645,409.80. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 3,009,847 shares of company stock valued at $389,142,882. Corporate insiders own 0.53% of the company’s stock.

CTLT has been the topic of a number of research analyst reports. Barclays initiated coverage on Catalent in a research report on Thursday, December 16th. They set an “overweight” rating and a $160.00 price target on the stock. Royal Bank of Canada increased their price objective on Catalent from $145.00 to $155.00 and gave the stock an “outperform” rating in a report on Wednesday, November 3rd. Zacks Investment Research upgraded Catalent from a “hold” rating to a “strong-buy” rating and set a $143.00 price objective for the company in a report on Tuesday, January 4th. Finally, Morgan Stanley increased their price objective on Catalent from $147.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, November 3rd. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $153.33.

CTLT stock opened at $108.24 on Friday. The company has a quick ratio of 3.02, a current ratio of 3.59 and a debt-to-equity ratio of 1.05. The business has a 50 day moving average price of $124.44 and a two-hundred day moving average price of $125.70. The company has a market cap of $18.53 billion, a price-to-earnings ratio of 34.15, a P/E/G ratio of 1.86 and a beta of 1.32. Catalent, Inc. has a twelve month low of $97.86 and a twelve month high of $142.64.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Monday, November 1st. The company reported $0.71 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.06. The firm had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.01 billion. Catalent had a return on equity of 14.64% and a net margin of 13.68%. During the same period last year, the company earned $0.33 earnings per share. On average, equities research analysts anticipate that Catalent, Inc. will post 3.51 EPS for the current fiscal year.

About Catalent

Catalent, Inc is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.

Further Reading: Market Indexes

Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent, Inc. (NYSE:CTLT).

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.